NCT06531629View on ClinicalTrials.gov

Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients

CompletedOBSERVATIONAL
Enrollment

72,408

Participants

Timeline

Start Date

January 1, 2000

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Kidney Cancer
Interventions
PROCEDURE

Surgery, radiation therapy and chemotherapy

Surgery, radiation therapy and chemotherapy

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT06531629 - Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients | Biotech Hunter | Biotech Hunter